| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Carrie McAdam-Marx | |
| Karen White | |||
| Holly E Gurgle | |||
| P2860 | cites work | Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study | Q59624425 |
| Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide | Q61836852 | ||
| Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors | Q63071417 | ||
| Standards of Medical Care in Diabetes-2016: Summary of Revisions | Q86960087 | ||
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 | ||
| Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus | Q33603466 | ||
| Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation | Q33636992 | ||
| Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance | Q33949418 | ||
| Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes | Q34402107 | ||
| Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. | Q34509910 | ||
| A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs | Q34543028 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Q34646948 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis | Q35227453 | ||
| Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective | Q35833876 | ||
| SGLT-2 Inhibitors: A New Mechanism for Glycemic Control | Q35906490 | ||
| Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program | Q35973246 | ||
| Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition | Q35973255 | ||
| Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study | Q36420499 | ||
| Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population | Q36444054 | ||
| Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). | Q37193446 | ||
| Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes | Q37331262 | ||
| Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing | Q37364896 | ||
| Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study | Q37627628 | ||
| The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review | Q37677051 | ||
| Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial | Q38405757 | ||
| Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. | Q39586526 | ||
| Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study | Q39905736 | ||
| DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks | Q40718093 | ||
| Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome | Q41078909 | ||
| The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus | Q41148389 | ||
| Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial | Q42671884 | ||
| Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial | Q42706050 | ||
| Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials | Q43446368 | ||
| Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia | Q43650443 | ||
| The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain | Q43878313 | ||
| Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes | Q44620317 | ||
| Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. | Q45990556 | ||
| Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. | Q46127637 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. | Q46493432 | ||
| Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials | Q46637270 | ||
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 | ||
| Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 | ||
| Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes | Q47581268 | ||
| Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). | Q48273566 | ||
| Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans | Q48440967 | ||
| Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus | Q51070885 | ||
| Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). | Q51332907 | ||
| Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. | Q51353951 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. | Q51743679 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood glucose | Q275157 |
| anti-diabetic medication | Q575062 | ||
| incretins | Q1420402 | ||
| proximal tubule | Q2916078 | ||
| type 2 diabetes | Q3025883 | ||
| Glucagon like peptide 1 receptor | Q5572289 | ||
| gliflozins | Q20089925 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 239-49 | |
| P577 | publication date | 2016-06-04 | |
| P1433 | published in | Vascular Health and Risk Management | Q7916443 |
| P1476 | title | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives | |
| P478 | volume | 12 |
| Q37685967 | ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes. |
| Q64110036 | Long-term safety and efficacy of the sodium glucose cotransporter 2 inhibitor tofogliflozin added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus (J-STEP/GLP): a 52-week open-label, multicenter, post-mar |
| Q92771709 | Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands |
| Q33859212 | SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study |
| Q92184218 | Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? |
Search more.